Demant Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Demant ha un patrimonio netto totale di DKK9.5B e un debito totale di DKK13.1B, che porta il suo rapporto debito/patrimonio netto a 137.5%. Le sue attività totali e le sue passività totali sono rispettivamente DKK32.4B e DKK22.9B. L'EBIT di Demant è DKK4.0B rendendo il suo rapporto di copertura degli interessi 7.8. Ha liquidità e investimenti a breve termine pari a DKK1.0B.

Informazioni chiave

137.5%

Rapporto debito/patrimonio netto

DKK 13.10b

Debito

Indice di copertura degli interessi	7.8x
Contanti	DKK 1.05b
Patrimonio netto	DKK 9.52b
Totale passività	DKK 22.87b
Totale attività	DKK 32.39b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( DKK10.7B ) di DEMANC superano le sue passività a breve termine ( DKK7.5B ).

Passività a lungo termine: Le attività a breve termine di DEMANC ( DKK10.7B ) non coprono le sue passività a lungo termine ( DKK15.4B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 126.5% ) di DEMANC è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di DEMANC è aumentato da 95.3% a 137.5% negli ultimi 5 anni.

Copertura del debito: Il debito di DEMANC è ben coperto dal flusso di cassa operativo ( 27.8% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di DEMANC sono ben coperti dall'EBIT ( 7.8 x copertura).

Demant Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Demant A/S Appoints Anne-Karen Hunt as President of Diagnostics Business Area, Effective 1 November 2024

Demant A/S Announces Board Changes

Demant A/S Updates Earnings Guidance for the Year 2024

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Less than half of directors are independent

Demant A/S Provides Earnings Guidance for the Year 2024

Investor sentiment improves as stock rises 21%

Anja Madsen Announces Not to Stand for Re-Election to the Board of Directors of Demant A/S

Less than half of directors are independent

Demant A/S to Report Nine Months, 2024 Results on Nov 04, 2024

Less than half of directors are independent

Demant A/S Provides Earnings Guidance for the Year 2023

Less than half of directors are independent

Now 21% undervalued

Demant A/S Announces Executive Changes

Less than half of directors are independent

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Now 22% undervalued

Less than half of directors are independent

Less than half of directors are independent

Demant A/S to Report Fiscal Year 2022 Results on Feb 07, 2023

Less than half of directors are independent

Demant A/S Revised Earnings Guidance for the Full Year of 2022

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Demant A/S Revises Earnings Guidance for the Full Year 2022

Less than half of directors are independent

Less than half of directors are independent

Demant A/S (CPSE:DEMANT) acquired remaining 80% interest in ShengWang for CNY.

Less than half of directors are independent

Demant A/S Appoints Niels Wagner to the Board of Directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Demant A/S Announces Update on Voluntary Field Corrective Action

Less than half of directors are independent

Demant A/Sreiterated Guidance for the Year 2021

Less than half of directors are independent

Less than half of directors are independent

Demant A/S Updates Earnings Guidance for the Year 2021

Independent Director has left the company

Independent Director has left the company

New 90-day high: kr.263

Full year 2020 earnings released: EPS kr.4.68 (vs kr.6.00 in FY 2019)

Revenue beats expectations

Demant A/S Announces Executive Changes

New 90-day high: kr.237

Demant Launches New Flagship Hearing aids

New 90-day high: kr.235

Demant A/S, Annual General Meeting, Mar 05, 2021

Demant A/S Revises Earnings Guidance for the Second Half of Fiscal Year 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane